-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
iNature
The "microbiota-gut-lymphoma axis" represents an interesting pathway for microbiota-mediated lymphomagenesis and intervention opportunities, but the significance of gut microbiota in natural killer/T-cell lymphoma (NKTCL) remains a mystery
.
On November 8, 2022, Zhang Mingming, Li Zhaoming of Zhengzhou University and Chen Weihua of Huazhong University of Science and Technology jointly published a report entitled "Gut microbiota as non- invasive diagnostic and prognostic biomarkers for natural killer/T- cell lymphoma" online at Gut (IF=32).
The study suggests that gut microbiota can serve as a noninvasive diagnostic and prognostic biomarker for natural killer/T-cell lymphoma
.
The study recruited a discovery cohort that included 30 treatment groups – naïve patients and 20 healthy controls (HCs), and a validation cohort that included 12 patients and 13 HCs
, respectively.
The authors performed "shotgun method" metagenomic sequencing on their fecal samples, analyzed their gut metagenomics using mOTUs2 V.
2.
5, and trained a patient stratification classifier
with all species-level classification features using the LASSO algorithm implemented by SIAMCAT.
The classifier of this study achieved an accuracy of 0.
868 under the receiver operating characteristic curve (AUROC) on the discovery cohort and 0.
910 AUROC accuracy on the validation cohort
.
To increase the sample size for model training, the authors retrained the LASSO classifier for NKTCL using all samples from both cohorts and achieved an accuracy
of 0.
813.
AUROC cross-validation, which strongly supports the role
of gut microbiota as a diagnostic biomarker for NKTCL.
of public gut microbiota.
The authors observed an overall false-positive rate (FPR) of 3.
1% for HC, but higher FPR in patients with several cohorts, particularly pancreatic cancer, Crohn's disease, and liver disease
.
These results imply a significant overlap of biomarkers between these diseases and NKTCL, which was confirmed by LEfSe analysis
.
Importantly, these biomarkers were consistently enriched/decreased in most cohorts, including the enrichment of oral-derived Veillonella and Streptococcus in patients, as well as known beneficial species in HCs, such as Faecalibacterium prausnitzii, Eubacterium rectale and Bifidobacte-rium adolescentis
。 These results suggest that the authors' classifier can accurately distinguish NKTCL patients from HCs; However, since there are biomarkers that are shared with other diseases, combining selected clinical indicators with microbiota biomarkers will help establish unique diagnostic models
.
The results of the relevant data (image from Gut) found that survival data for NKTCL patients in the cohort were available
.
Of note, many identified biota biomarkers, particularly those shared by multiple diseases, can significantly predict overall survival (OS) and progression-free survival (PFS) in patients, including Streptococcus paraserpentineus, timmonensis, and Dyspores (Figures 1A-D
on Supplement).
。 Finally, the authors established the Streptococcus parasanguinis, Romboutsia timonensis, and Veillonella atypica index (SRI) as the relative abundance ratios of the two species, yielding the best predictive power
than other individual species and combinations.
That is, patients with NKTCL with higher SRI scores had significantly lower OS and PFS than patients with
lower SRI scores.
In addition, the authors observed a significant correlation
between high SRI scores and multiple adverse prognostic factors for NKTCL.
In conclusion, the results of this study support the use of intestinal flora as an effective auxiliary diagnostic tool
for NKTCL.
In addition, SRI scores based on shared biomarkers may have broad utility in the prognosis of multiple diseases and warrant further investigation
.
Original link: https://gut.
bmj.
com/content/early/2022/11/08/gutjnl-2022-328256?rss=1—END—the content is [iNature].
